Dental caries is an infectious disease that is continuing to increase in prevalence, reducing the quality of life for millions worldwide as well as causing considerable expense, with an estimated US$108 billion spent on dental care in the USA each year. Oral probiotics are now being investigated to determine whether they could play a role in the prevention and treatment of this disease. Streptococcus salivarius strain JH is a potential probiotic candidate that produces multiple proteinaceous antimicrobials (bacteriocins), the inhibitory spectrum of which includes Streptococcus mutans, one of the principal causative agents of dental caries. The genome of strain JH has previously been shown to contain the biosynthetic loci for the bacteriocins salivaricin A3, streptin and streptococcin SA-FF22. Here we show that strain JH also produces salivaricin E, a 32 aa lantibiotic with a mass of 3565.9 Da, which is responsible for the inhibition of S. mutans growth. In addition, strain JH was shown to produce dextranase, an enzyme that hydrolyses (1R6)-a-D-glucosidic linkages, at levels higher than any other S. salivarius tested.
INTRODUCTION
The human oral microbiome comprises at least 700 currently recognized bacterial species, the majority of which are niche-adapted oral cavity commensals, but also including a variable subset of potentially pathogenic species that are operationally maintained in a quasi-equilibrium carriage state (Aas et al., 2005) . Most oral cavity infections are characterized by disturbance to homeostasis or oral dysbiosis caused by overgrowth of one or more pathogenic bacterial species. Taking steps to strengthen oral homeostatic mechanisms may reduce infection development. One way to do this is through the use of probiotics, now officially defined as 'live microorganisms, which when administered in adequate amounts, confer a health benefit on the host' (Araya et al., 2002) . Research into probiotics first focused on the gastrointestinal tract (Nagpal et al., 2012) , but more recently probiotics specific to the oral cavity have also been developed (Burton et al., 2006; Wescombe et al., 2009; Zahradnik et al., 2009) . Streptococcus salivarius K12, the prototype of these oral probiotics, has been shown to have both in vitro and in vivo inhibitory activity against important oral pathogens, including Streptococcus pyogenes (Hyink et al., 2007) and Streptococcus pneumoniae (Power et al., 2008) .
Although the aetiology of dental caries is both complex and multifaceted, elevated plaque levels of the mutans streptococci (MS) and especially of Streptococcus mutans have long been used as an index of cariogenic activity (Hamada & Slade, 1980; Loesche, 1986) . A characteristic of the MS that contributes to their pivotal role in dental caries is their formation of both soluble and insoluble glucan components of the exopolymeric substance (EPS) matrix of dental plaque. Glucans are synthesized by glucosyltransferases (GTFs), and S. mutans possesses three of these enzymes, producing water-insoluble (GTF-B) or soluble (GTF-D) glucans or a combination of both (GTF-C) (Aoki et al., 1986; Hanada & Kuramitsu, 1988 , 1989 . The insoluble glucan is predominantly mutan [(1R3)-a-D-glucosidic polymers], while soluble glucan largely comprises dextran [(1R6)-a-D-glucosidic polymers] (Kopec et al., 1997) .
The oral cavity application of bacterially derived ribosomally synthesized antimicrobial agents (bacteriocins) having specificity for MS has been explored as one potential means of controlling dental caries (Balakrishnan et al., 2001; Chikindas et al., 1997; James & Tagg, 1991 ). An early candidate was zoocin A, a large (27 kDa) muralytic bacteriocin exhibiting relatively specific activity against both S. mutans and S. pyogenes (Simmonds et al., 1995) . More recently, the two-component bacteriocin lacticin 3147 was shown to effect a fourfold reduction of S. mutans levels in an in vitro human saliva-based model (O'Connor et al., 2006) . In another approach, a bacteriocin-producing S. mutans was genetically modified to create a variant having reduced cariogenic potential for proposed application in a strain-replacement therapeutic strategy for dental caries control (Hillman, 2002) .
Oral probiotics could potentially reduce oral MS levels by either (a) directly out-competing MS for their favoured ecological niche within dental plaque, or (b) producing extracellular substances that diffuse into and kill MS within the plaque matrix. The probiotic S. salivarius K12 has some relatively weak in vitro inhibitory activity against MS. In the present study, we report that a new oral probiotic candidate, S. salivarius strain JH, has more potent anti-MS activity than strain K12 owing to its production of a novel lantibiotic bacteriocin, salivaricin E (SalE). We also show that strain JH is distinctive in that it produces more dextranase activity than any other S. salivarius tested. The substrate for this enzyme, dextran, is a major component of the EPS matrix of dental plaque. Furthermore, preparations of dextranase from strain JH were shown to enhance the inhibitory activity of zoocin A against MS embedded within an EPS matrix in an in vitro test system. The production of novel anti-MS bacteriocin activity, and high levels of EPS hydrolytic activity, support the candidature of strain JH as an oral probiotic.
METHODS
Bacterial strains and culture parameters. S. salivarius strain JH (Tompkins & Tagg, 1987) was the focus of this study, owing to its particularly strong dextranase activity and its production of novel bacteriocin-like inhibitory substance (BLIS) activity against MS. 2  2  2  2  2  2  2  2  193  777  +  2  2  2  2  2  2  +  2  MPS  400  +  2  2  2  2  2  2  +  2  PT4  667  2  2  2  2  2  2  2  2  2  TOVE-R  657  2  2  2  2  2  2  2  2  2  JIM8777  400  2  2  2  2  2  2  2  2  2  Pirie  401  2  2  2  2  2  2  2  2  2 *Clearance of BD scored as: 2, no hydrolysis; +, zone up to 1 mm from the edge of producer streak; ++, zone of 2-3 mm from edge of producer streak; +++, zone of 4-5 mm from edge of producer streak. DMean (typical) result for given agar/incubation conditions. Inhibition zone size: 2, no zone; +, less than the width of producer streak; ++, width of producer streak; +++, up to 5 mm wider than the producer streak; ++++, greater than 5 mm wider than the producer streak.
Other S. salivarius strains evaluated for their dextranase and anti-MS BLIS activities are listed in Table 1 . The nine standard indicator bacteria (I1-I9) used for BLIS P-typing have been described previously (Tagg & Bannister, 1979) . S. pyogenes strain EB1 (Tagg & Wannamaker, 1976 ) is a bacteriocin-negative derivative of S. pyogenes strain FF22 (standard indicator I2) (Tagg & Wannamaker, 1976) . The EPS-producing S. mutans strain MT703 was used in the in vitro biofilm model. S. mutans strain Ny266 was the source of the small (2270 Da) bacteriocin mutacin B-Ny266 (Mota-Meira et al., 1997), and Streptococcus equi subsp. zooepidemicus strain 1554 produces the 27 kDa muralytic bacteriocin zoocin A (Simmonds et al., 1995) .
Incubation of all cultures was for 18-24 h in an atmosphere of 5 % CO 2 in air at 37 uC. Routine propagation of all strains was on Columbia blood agar base (Difco) supplemented with 5 % (v/v) human blood and 0.1 % (w/v) CaCO 3 (BACa). Other media used were Todd-Hewitt broth (THB; Difco), tryptic soy broth (TSB; Difco) with 2 % (w/v) yeast extract (YE), and 0.25 % (w/v) CaCO 3 (Ca) supplemented with 1.5 % (w/v) agar (TSBYECa). Dextranase production medium (DPM) was modified from Donkersloot & Harr (1979) . A 10| stock solution comprising 50 g TSB l 21 without glucose, 50 g yeast extract l 21 , 50 g K 2 HPO 3 .3H 2 O l 21 and 0.5 g Na 2 CO 3 l 21 was prepared in MilliQ ultrapure water. The 10| stock solution (200 ml) was dialysed against 1.8 l MilliQ ultra-pure water using 32 mm-wide 8000 Da molecular mass cut-off dialysis tubing. The resulting dialysate was then adjusted to pH 6.8 with 11 M HCl and sterilized by autoclaving. Filter-sterilized lactose (20 %, w/v, stock solution) was then added to yield a final concentration of 1 % (w/v).
Deferred antagonism assay. The method of deferred antagonism originally described by Tagg & Bannister (1979) was used either to determine the producer-type (P-type) of BLIS activity of the test strains or to compare the relative susceptibilities of different bacterial strains to BLIS activities produced in agar media. Briefly, the test strain was inoculated diametrically across the surface of BaCa medium as a 1 cm-wide streak. After incubation, the test strain growth was removed using a glass slide and the agar surface was sterilized by exposure to chloroform vapours for 30 min. The plate was then aired for 15 min before 18 h THB cultures of the indicator strains were inoculated across the line of the original producer growth. The plates were then re-incubated for 24 h and the indicator streaks examined for zones of inhibited growth. These were graded as: 2, no inhibition; +, zone less than the width of the producer streak; ++, zone the same width as the producer streak; +++, zone up to 5 mm wider than the producer streak; ++++, zone w5 mm wider than the producer streak. In order to establish the P-type designation, inhibitory activity of at least ++ strength against an indicator was recorded in code form (the P-type) by considering the indicators as three triplets (i.e. I1, I2, I3; I4, I5, I6; and I7, I8, I9). Inhibition of ++ or stronger of the first member of a triplet was given a score of 4, the second a score of 2, and the third a score of 1. Absence of at least ++ inhibitory action against an indicator was scored as 0. The P-type code was then recorded as the sequence of three numbers representing the scores for each triplet. All deferred antagonism tests were performed in duplicate, and further testing was undertaken until consistent inhibition patterns were obtained.
Isolation and partial biochemical characterization of SalE.
S. salivarius JH was grown as lawn cultures on 20 plates of TSBYECa using fresh (18-24 h) TSBYECa cultures of strain JH as the inoculum source. The cells were collected from the 20 lawn cultures using cotton swabs and then were resuspended in 10 ml 95 % acidified (pH 2) methanol. These preparations were allowed to stand at 4 uC for 4 h, then centrifuged at 16 100 g for 5 min prior to testing the supernatant for BLIS activity by the spot inhibitory assay. The BLIScontaining supernatant was concentrated tenfold by evaporation under vacuum using a vacuum concentrator (Eppendorf concentrator 5301). Aliquots (1 ml) of crude inhibitor preparation were added to a pretreated (5 ml 80 % methanol, followed by 5 ml MilliQ water) SepPak C18 Cartridge (Waters). Activity was eluted by subsequent 4 ml washes with 50, 60, 70 and 80 % methanol and 95 % (pH 2) methanol, after which the column was flushed with 4 ml MilliQ water. Each fraction was spot-plate assayed. Active fractions were further purified by HPLC on a C18 reversed-phase column (Phenomenex Jupiter C18 column, 5 mm, 300 Å , 250|4.6 mm) using a gradient of 25-40 % acetonitrile over 50 min and a flow rate of 1 ml min 21 . Fractions having inhibitory activity against Micrococcus luteus and S. mutans strain OMZ175 were further analysed by MALDI-TOF (matrix-assisted laser desorption-time of flight) mass spectrometry at the Centre for Protein Research, Department of Biochemistry, University of Otago (Hubbard & McHugh, 1996) .
Identification of the locus encoding SalE. A partial genome sequence of S. salivarius strain JH assembled from whole-genome sequencing using a Roche GS-FLX pyrosequencer (Heng & Stanton, 2010) was screened for lanA homologues. A locus containing 14 genes, including srnA, was identified using a combination of BLASTN, BLASTX and BLASTP searches (Altschul et al., 1997) against the GenBank database at the National Center for Biotechnology Information (NCBI; http://blast.ncbi.nlm.nih.gov/Blast.cgi). Areas of questionable sequence quality were confirmed by Sanger-based sequencing of PCR amplicons generated using primers flanking regions of interest. The GenBank/EMBL/DDBJ accession number for the SalE genetic locus is KT032116.
In vitro model for the evaluation of bacteriocin activity against EPS-producing bacteria. The bacteriocin-producing strain was inoculated as a 1 cm diametric streak on the base TSBYE agar. Following incubation, the producer growth was removed and the agar surface sterilized by exposure to chloroform vapours, as in deferred antagonism testing (see above). A soft agar overlay of 9 ml TSBYE (prepared using 0.75 %, w/v, agar with or without 5 %, w/v, sucrose or lactose supplement) was then poured over the base agar and left for 2 h at room temperature to allow bacteriocin diffusion to occur. TSBYE cultures of eight MS and one bacteriocin-sensitive non-EPSproducing streptococcus (S. pyogenes strain EB1) were then inoculated perpendicularly across the line of the original producer streak culture. Following overnight (24 h) incubation, the width of the inhibition zone of each indicator was measured and graded as 2,+,++,+++ or ++++, as described for the deferred antagonism assay (above).
Purification of S. salivarius strain JH dextranase. Flasks containing 400 ml DPM (pre-reduced by incubation for 24 h in an anaerobic atmosphere) were inoculated with 200 ml of a 24 h THB culture of the test strain of S. salivarius, followed by anaerobic incubation at 37 uC for 24 h. The supernatant was then recovered by centrifugation at 8275 g for 25 min and stored at 4 uC. Ammonium sulphate was added to achieve 70 % saturation, and the precipitate, which formed overnight at 4 uC, was collected by centrifugation at 8275 g for 40 min and redissolved in approximately one-hundredth of the starting volume of 50 mM Tris/HCl (pH 8) (Buffer A). These crude preparations were assayed for dextranase activity on blue dextran agar (BDA), which is a modification of the agar medium described by Donkersloot & Harr (1979) , whereby (i) 5 g l 21 TSB without glucose was used instead of the trypticase, and (ii) glucose was replaced by 1 % (w/v) lactose (from a filter-sterilized 20 %, w/v, lactose stock solution).
For purification of the strain JH dextranase, the concentrate obtained by ammonium sulphate precipitation was first desalted and equilibrated with Buffer A using Vivaspin 20 50 kDa molecular mass cut-off centrifugal concentrator tubes (GE Healthcare Life Sciences). Centrifugation was for 15-25 min at 1800 g using an Eppendorf 5810 centrifuge.
Ion-exchange chromatography of the Buffer A-equilibrated preparation was conducted on a Bio-Rad Macro-Prep DEAE ion exchange resin column. An 8 ml bed volume of resin was adjusted to pH 8.0 by washing with 12 column volumes (96 ml) Buffer A. Desalted protein preparations (each ca 16 ml) were loaded onto the pre-washed resin and allowed to pass through the column in order to bind the dextranase. This was followed by 48 ml Buffer A and then a sequential step (8 ml per step) gradient of Buffer A containing 0.25, 0.5, 1.0, 1.5 and 2.0 M NaCl (Buffer B), respectively. Aliquots from each 2.5 ml eluent fraction were tested for dextranase activity by a well assay on BDA as follows.
Dextranase well diffusion assay. Full-depth wells were cut in a plate of BDA using a hollow glass rod (Pasteur pipette, 6 mm diameter). After removing the agar plugs, the base of each well was sealed by the addition of one drop (approx. 20 ml) of molten agar (1.5 %, w/v) from a Pasteur pipette. Fifty-microlitre samples of preparations to be tested for dextranase activity were added to the appropriate wells. Incubation was at 37 uC in air in a humid environment (to prevent agar desiccation). Dextranase activity was evident as a reduction of the blue colour of the BDA surrounding a test well, and an associated 'halo' effect in the dye front formed by diffusion of the released dye.
Effect of dextranase pretreatment on the penetration of zoocin
A through an EPS-containing matrix. Glass fibre filters (47 mm diameter GF/A; Whatman) were washed thoroughly in distilled water then sterilized by autoclaving at 121 uC for 15 min. A 10 ml glucosefree TSB culture of S. mutans MT703 was transferred to a Petri dish into which the glass fibre filters were successively dipped, and after 30 s the excess liquid was drained prior to the filters being placed on the surface of a nutrient agar plate [either TSBYE plus 5 % (w/v) sucrose (for EPS production) or TSBYE only (control)]. A minimum of two test plates and two control plates was used in each experiment.
The plates were incubated for 48 h at 37 uC in 5 % CO 2 in air to allow EPS formation within the glass fibre matrix. After incubation, the filters were sterilized by exposure to chloroform vapour for 30 min and then placed on buffered agar (50 mM TES buffer pH 6.8, in 1.5 %, w/v, Davis agar) for 1 h at room temperature to allow pH equilibration and evaporation of any residual chloroform. The filters were then transferred onto the surface of TSBYE agar and 10 ml volumes of a twofold dilution series of bacteriocin preparation were spotted onto the surface of the filter. After 30 min at room temperature the filters were removed and discarded. The agar surface was sterilized with chloroform vapour, then a bacteriocin-sensitive lawn culture was seeded onto the agar using a cotton swab charged by immersion into a 1 : 300 dilution of a TSBYE culture of S. mutans MT703. Following incubation, the bacteriocin titre was assessed. The difference in bacteriocin titre between the test and control plates provided a measure of the influence of EPS on bacteriocin penetration of the matrix.
Saliva model. To test for dextranase and BLIS activity in saliva, test strains were inoculated into 3 ml THB and incubated for 24 h at 37 uC in 5 % CO 2 . An aliquot (0.5 ml) of the 24 h culture was added to 8.325 ml of filtered (0.45 mm pore size) sterilized saliva that was supplemented with 1 ml 0.5 M CaCO 3 , 100 ml 500 mg ml 21 cysteine and 75 ml 10 % (w/v) glucose for a total volume of 10 ml. The test system was mixed by inversion and then incubated at 37 uC in 5 % CO 2 for 5 h, after which the saliva culture was centrifuged at 9820 g for 5 min and the supernatant serially diluted twofold to 1 : 16. Samples of each dilution were tested for dextranase activity on BDA using the well diffusion assay or on BACa for BLIS activity.
RESULTS AND DISCUSSION
Evaluation of production of anti-MS BLIS and dextranase activities by S. salivarius strains To identify a suitable candidate S. salivarius strain for potential use as an anti-dental-caries probiotic, a selection of previously identified BLIS-producing S. salivarius, exhibiting a variety of inhibitory patterns (P-types) against a set of nine standard BLIS indicator strains, were tested for anti-MS BLIS activity using the deferred antagonism method (Table 1) . The most broadly active of the strains tested was the P-type 777 S. salivarius strain JH, which was inhibitory to six of the eight MS indicators. S. salivarius strains K12, Min5, GR, #6 and #36 each inhibited only four of the MS indicators. Interestingly, the six strains inhibitory to all nine standard indicators (P-type 777) had widely different activity spectra against the eight MS indicators, ranging from inhibition of one (strain NR) to six (strain JH) MS strains. By contrast, although strains GR, #6 and #36 had markedly different P-type designations, they exhibited closely similar anti-MS spectra. Each of the test strains was evaluated for dextranase activity and six (39 %) were positive (Table 1) . No direct correlation was evident between the production of dextranase and the spectrum of anti-MS activities; indeed, three of the dextranasepositive strains showed no detectable BLIS activity against the MS indicators. S. salivarius strain JH was selected for further characterization as it was the strongest producer of both anti-MS and dextranase activities of the 18 S. salivarius strains tested. As part of this additional evaluation, a broader selection of oral bacterial species were tested for sensitivity to strain JH in order to help establish the probiotic potential of the strain compared to the gold standard oral probiotic strain K12 (Table 2) . Strain JH exhibited a broad spectrum of inhibitory activity against both commensal and potentially pathogenic species, with sensitive strains evident in the species Streptococcus anginosus, Streptococcus constellatus, Streptococcus mitis, Streptococcus oralis, S. pneumoniae, S. pyogenes, Streptococcus sanguinis and Streptococcus sobrinus. Importantly, strain JH was inhibitory to more MS than strain K12, and also inhibited all tested isolates of the infection-incriminated species S. pyogenes, S. pneumoniae and S. anginosus. Interestingly, a smaller proportion (2/10) of a set of freshly isolated S. mutans appeared sensitive to strain JH as compared to laboratory-passaged S. mutans (8/9). This indicates that, although strain JH appears to have good potential for development as an oral cavity probiotic owing to its broad activity against upper respiratory tract pathogens, its applicability to S. mutans control still requires further evaluation, perhaps using in vitro artificial plaque models and preliminary small-scale studies with human subjects. It will be particularly important, of course, to establish whether probiotic-induced shifts within the plaque composition could potentially result in the selection of populations that, in addition to being relatively insensitive to strain JH inhibitors, are also of increased cariogenicity.
Isolation and partial characterization of the anti-MS bacteriocin SalE
To identify the molecule responsible for the anti-MS inhibitory activity, extracts were obtained by harvesting S. salivarius strain JH cells from lawn cultures grown on TSBYECa and resuspending them in acidified (pH 2) 95 % methanol. After removal of the methanol and processing on Sep-Pak columns, the titre of these preparations against S. mutans OMZ175 and M46 was typically 16. Purification of the anti-MS inhibitory agent(s) was achieved by C18 reversed-phase HPLC (Fig. 1) , the principal inhibitory activity against S. mutans OMZ176 eluting in ca 30 % acetonitrile as a single absorbance peak at 214 nm. MALDI-TOF mass spectrometry of the inhibitory fraction yielded a mean mass of 3565.9 Da. The purified inhibitory peptide, designated salivaricin E (SalE), was subjected to N-terminal sequencing by Edman degradation (Fig. 2a) . This established that the first 24 aa directly corresponded to those predicted by the translated ORF for SrnA (Fig. 2a) . The four blank calls from N-terminal sequencing are consistent with the peptide containing three thioetherlinked lanthionine or b-methyl-lanthionine residues.
Identification of the SalE genetic locus
Previous investigations of S. salivarius JH showed that three bacteriocin loci (salivaricin A3, SA-FF22 and streptin) were localized to a 220 kb megaplasmid (Wescombe et al., 2006a, b) . Further analysis of this megaplasmid sequence following partial genome sequencing revealed an additional locus (designated the Srn locus), typified by srnA, which encodes the deduced amino acid sequence for SalE (Fig. 2b) . Flanking the srnA structural gene are two putative variants (srnA' and srnA''). Whereas the translated product of srnA' differs from SalE by a single amino acid (Fig. 2b) , the peptide specified by srnA'' differs more extensively. The hypothetical leader sequences for SrnA' and SrnA'' both differ considerably from that of SalE, which may result in these variants not being exported from the bacterial cell. Further upstream of srnA are four ORFs encoding a putative Tn916-like transposase (ORF1), a truncated protein kinase (ORF2), an XRE-like protein transcriptional regulator (ORF3) and a transcriptional repressor (ORF4). Whilst the presence of the transposase suggests that the srn locus may have been acquired via a transposition event, the functions of ORF2-ORF4, if any, remain unknown. Downstream of srnA'' are ORFs that typically encode proteins associated with the biosynthesis of lantibiotic peptides. These comprise: (a) an ABC transporter ATP-binding protein (srnX) and an ABC transporter permease (srnY), both of which may play a role in producer self-protection (immunity) to SalE; (b) a histidine kinase (srnK) and a response regulator (srnR), which together are likely to control the expression of the SalE locus in response to an as yet unknown external signal; (c) a lantibiotic modification enzyme (srnM), likely to be responsible for the formation of the lanthionine rings characteristic of lantibiotics; and (d) an ABC transporter expected to be involved in the export of SalE (srnT). The presence of srnM, encoding a single putative post-translational modifying enzyme, and srnT, encoding a putative dual-acting ABC transporter, categorizes SalE as a class II lantibiotic (Willey & van der Donk, 2007) . The role of ORF5, which encodes a putative and SalE'' prepropeptides. Translated sequence homologous to that obtained by N-terminal sequencing is highlighted in black. Light grey-highlighted residues indicate the differences among SalE, SalE' and SalE'' prepeptide leader sequences. Medium grey highlights sequence differences between SalE and SalE', while dark grey highlights amino acid differences between the SalE and SalE'' propeptides. Expected prepeptide leader sequences are underlined. 'X' in the Edman N-terminal sequence corresponds to unidentified amino acids whose locations are consistent with chemically modified amino acids as referred to in the text. Transl., Translated.
(b) Schematic of the SalE genetic locus and flanking ORFs. The number of amino acids specified by each gene/ORF is also shown below the mapline.
isomerase homologue, is unknown; ORF5 represents the 39 boundary of the bacteriocin locus.
The relative similarity of the SalE propeptide to other salivaricins was determined using BLASTP and demonstrates that SalE is a novel lantibiotic (Fig. 3) . The greatest similarity is to salivaricin M (53 % identity), while the next closest match, with 50 % identity, is salivaricin D (GenBank accession number AEX55166), followed by salivaricin A (GenBank accession number AY005472) and salivaricin G32 (GenBank accession number JN831266), both with 43 % identity.
The influence of EPS production on bacteriocin sensitivity of MS
We hypothesized that an oral probiotic strain capable of producing dextranase would disrupt the dextran matrix within dental plaque, and enhance the accessibility of caries-causing bacteria in a plaque biofilm to the action of antimicrobial agents. To address this hypothesis, an in vitro test system was developed to assess whether bacteriocin activity against MS is diminished when the target bacteria are grown under conditions favourable to the production of EPS. It was discovered that strain JH did not perform well in this assay system, failing to produce consistent levels of anti-MS inhibitory activity in the test system owing to the composition of the agar medium required. Therefore, two well-characterized anti-MS bacteriocins, zoocin A (27 000 Da) and mutacin B-Ny266 (2300 Da), were selected as the prototype high-and lowmolecular mass bacteriocins for evaluation of the assay.
The effectiveness of the assay for detecting the role of EPS in the reduction of sensitivity of MS to the bacteriocins was investigated by comparing medium supplemented with sucrose (encourages EPS production) against medium supplemented with lactose, which cannot be used by MS indicator MT703 for the production of EPS. The activity of zoocin A against strain MT703 was not affected by the lactose-supplemented overlay as compared with the carbohydrate-free control, but was completely eliminated by the presence of sucrose (Table 3) . This indicates that it was the EPS produced by the indicator on the sucrose-supplemented medium that interfered with zoocin A activity, whereas the action of the much smaller lantibiotic bacteriocin mutacin B-Ny266 was relatively unaffected against the indicator MT703.
The sucrose-supplemented agar overlay method was then used to test the anti-MS activities of a variety of BLIS-producing streptococci to determine the potential protective inhibition zones on the sucrose-supplemented agar. The six other bacteriocin-producing strains that appeared to have their inhibitory spectra reduced when the indicator bacteria were grown in conditions conducive to EPS production were: JH (activity lost against five indicators); N (activity lost against one EPS-producing indicator); BHT (activity reduced against two indicators and lost against two others); UA140 (activity reduced against one indicator strain); M19 and 4N (activity lost against one indicator strain). Interestingly, although activity was reduced for these six strains, inhibition of the non-EPSproducing indicator strain EB1 was unaffected, except for strain M19, indicating that, for this strain, the absence of observable activity may not be completely explained by the production of EPS. It appears that this assay system may be a useful method for identifying strains that produce more than one anti-MS BLIS. For example, S. rattus strain BHT, which is known to produce multiple bacteriocins (Hyink et al., 2005) , retained full activity against some indicator strains while failing to inhibit others, indicating that the different bacteriocins are not affected by the presence of EPS to the same extent. The fact that 8 of the 13 strains tested had narrower spectra of activity against MS in the presence of EPS-conducive growth conditions indicates that the presence of EPS does reduce the sensitivity of bacteria to certain antibacterial agents, and therefore is likely to be ecologically significant for the survival and proliferation of MS in the oral cavity.
S. salivarius dextranase activity in the presence of saliva A comparison of the levels of dextranase activity produced in DPM (Table 5 ) by selected S. salivarius showed that strain JH was 8-and 16-fold more active, respectively, than strains K12 and PC-1 (the prototype producer of S. salivarius dextranase). S. salivarius strain JIM8777, despite the presence of an apparently complete dextranase locus in its genome (Guédon et al., 2011) , produced no detectable dextranase activity. Interestingly, when strains JH and K12 were tested in the saliva model, dextranase activity of titres 3200 and 200, respectively, was observed (Table 4 ), indicating that certain factors in saliva significantly enhance the expression of dextranase activity by S. salivarius. This observation provides support for direct in vivo assessment of the impact of strain JH on MS populations in the oral cavity, as it indicates that our in vitro models may not accurately reflect the enzymic and bacteriocin production capabilities of strain JH in the human oral cavity. Since strain JH was found to produce the highest yield of dextranase, it was used as the source of dextranase for incorporation in an experimental model to assess the benefits of dextranase disruption of bacterial EPS to enhance the effectiveness of bacteriocin activity against MS.
Effect of dextranase pretreatment on the penetration of zoocin A through an EPS-containing matrix
A glass fibre filter model system was developed and used to quantify the effect of dextranase pretreatment of EPS-containing matrices on zoocin A penetration. The zoocin A preparation, when passed through glass fibre filters containing no EPS, had a mean MIC of 62.5 arbitrary units (AU). When EPS was present in the glass fibre matrix as a result of bacterial growth in the presence of sucrose, the MIC increased 2.5-fold to a mean of 156.25 AU. Pretreatment of the EPS-containing glass fibre filters using dextranase sourced from strain JH restored the MIC to 62.5 AU, thereby supporting the hypothesis that dextranase treatment can be used to improve the effectiveness of anti-MS bacteriocins in EPS-containing biofilms.
CONCLUDING REMARKS
In the present study, we have shown that the candidate oral probiotic S. salivarius JH produces important in vitro inhibitory activity not only towards the common upper respiratory tract pathogens S. pyogenes and S. pneumoniae, but also towards strains of S. mutans and S. sobrinus, the principal species of MS associated with human dental caries. This anti-MS activity appears, at least in part, attributable to the production of SalE, a newly described 3565.9 Da class II lantibiotic bacteriocin. The genetic locus specifying the biosynthesis of SalE is located on the 220 kb megaplasmid pSsal-JH, previously shown to also harbour the loci for the bacteriocins salivaricin A3, SA-FF22 and streptin (Wescombe et al., 2006a) .
Strain JH has also been demonstrated to produce the EPShydrolysing enzyme, dextranase, in larger amounts than any other tested S. salivarius. Hydrolysis of S. mutansproduced EPS by strain JH dextranase enhanced the susceptibility of MS to the inhibitory activity of zoocin A, a bacteriocin previously investigated for potential application to the control of dental caries (Simmonds et al., 1995) . Our present findings indicate that exposure of biofilms to EPS-hydrolysing enzymes such as dextranase may increase the matrix penetration and killing efficacy of some anti-bacterial agents. The relatively broad inhibitory spectrum towards oral pathogenic bacteria, and in vitro production of unusually high levels of dextranase activity by strain JH, encourage us to recommend that the probiotic potential of this strain be further investigated in pilot studies with human subjects.
The focus of these studies should be an evaluation of the effect of strain JH consumption on plaque formation, and on modulation of the composition of the oral microbiota, with emphasis perhaps on any changes effected in the mutans streptococcal populations of the host.
